SHANGHAI  April 16  2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab")  a biotech company focusing exclusively on innovative biologics in immuno-oncology and auto-immune diseases  and WuXi Biologics ("WuXi Bio") (2269HK)  a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery  development and manufacturing  jointly announce today that the two companies have entered into a long-term strategic partnership on biologics process development  clinical and commercial manufacturing of I-Mab's highly innovative pipelines